Patent ID: 8124332

Claim:
A method of monitoring the necessity for administering a CD26 inhibitor to a patient who is in need of receiving an effective amount of a CD26 inhibitor, the method comprises: recovering samples from the patient and a control, wherein the control is at least one control selected from a healthy individual and a patient having cleared infection, inactivating the intrinsic dipeptidylpeptidase IV (DPPIV), detecting levels of a long form of interferon-gamma induced protein-10 (IP-10), which is a full length form of a secreted bioactivated IP-10 with 77 amino acids, and a short form of IP-10 (sIP-10), which is a N-terminal truncated antagonist of the long form of IP-10 lacking 2 or 4 amino acids from the N-terminus of the long form of IP-10, in the patient and control, and comparing the levels and ratios of sIP-10 and the long form of IP-10, wherein an elevated level of antagonist forms of IP-10 (sIP-10) relatively to the level of the long form of IP-10 in the patient indicates the necessity of administering a CD26 inhibitor.